http://www.fpnotebook.com/
Lung Cancer
Aka: Lung Cancer, Lung Carcinoma, Bronchogenic Carcinoma, Small Cell Lung Cancer- See Also
- Epidemiology
- Lung Cancer is the top U.S. cause of cancer death
- Exceeds deaths from combination of 3 cancers
- Incidence: 172,000 in U.S. in 1999
- Mortality: 158,000 in U.S. in 2006
- Pathophysiology
- Hematogenous seeding occurs at 1-2 mm
- Earliest detection of Tumor by CT Chest: 2 mm
- Tumor 1 cm size shed 3 to 6 million cells daily
- Risk Factors
- Tobacco abuse (Relative risk 10-30)
- Women: Tobacco directly linked in 90% of cases
- Men: Tobacco directly linked in 79% of cases
- Passive Smoke Exposure
- Asbestos Exposure
- Relative risk in non-smokers: 6
- Relative risk in smokers: 60
- Other associated environmental exposures
- Comorbid lung disease
- Tobacco abuse (Relative risk 10-30)
- Types
- Small Cell Lung Cancer (20% of Lung Cancer)
- Non-Small Cell Lung Cancer (75% of Lung Cancers)
- Squamous Cell Carcinoma
- Adenocarcinoma
- Large cell carcinoma
- Symptoms (present in 90% at time of diagnosis)
- Constitutional symptoms
- Fatigue
- Anorexia
- Weight loss
- Cardiopulmonary symptoms
- Chest Pain (50%)
- Cough (75%)
- Dyspnea (60%)
- Hemoptysis (35%)
- Constitutional symptoms
- Presentations: Intrathoracic spread (40% at diagnosis)
- Nerve injury
- Recurrent laryngeal nerve paralysis (Hoarseness)
- Phrenic nerve lesion
- Left diaphragm elevated
- Dyspnea
- Brachial Plexus Injury
- Presents as Horner Syndrome
- Associated with Pancoast's tumor
- Chest wall invasion
- May present as Pleuritic Chest Pain
- Pleural Effusion
- Esophageal obstruction
- Superior Vena Cava Obstruction
- Nerve injury
- Presentations: Extrathoracic spread (33% at diagnosis)
- Long bone or Vertebral pathologic Fractures
- Supraclavicular Lymphadenopathy
- Liver metastases (liver transaminases rarely increased)
- Brain metastases (10%)
- Spinal column
- Lymph nodes
- Adrenal Glands
- Presentation: Paraneoplastic Syndromes (10% at diagnosis)
- Hypercalcemia
- Syndrome of inappropriate antidiuretic hormone
- Cushing's Syndrome
- Hypertrophic pulmonary Osteoarthropathy (Clubbing)
- Lambert-Eaton myasthenia syndrome
- Diagnosis
- Non-invasive measures
- Sputum Cytology
- Test Sensitivity for central tumors: 71%
- Test Sensitivity for central tumors: 50%
- Sputum Cytology
- Less invasive measures
- Pleural EffusionThoracentesis
- Excisional Biopsy (if node accessible)
- Bronchoscopy with Bronchial samples and biopsy
- Indicated for central tumors
- Test Sensitivity for central lesions: 88%
- Test Sensitivity for peripheral lesions: 70%
- Transthoracic needle aspiration
- Indicated for peripheral lesions
- Test Sensitivity for peripheral lesions: 90%
- Thoracotomy
- Indicated for non-small cell carcinoma
- Lesion amenable to surgery
- Non-invasive measures
- Staging
- Non-Small Cell Lung Cancer
- See Non-Small Cell Lung Cancer for staging
- Small Cell Lung Cancer
- Limited: Lesion confined to ipsilateral chest
- Extensive: Metastases beyond ipsilateral chest
- Non-Small Cell Lung Cancer
- Labs: Evaluation for metastases
- Complete Blood Count
- Serum electrolytes
- Serum Calcium
- Liver Function Tests
- Imaging: Evaluation for metastases
- Diagnostics: Pulmonary Function Tests
- Initial Testing
- FEV1
- DLCO
- Second-line testing (indicated for DLCO or FEV1 <80%)
- Cardiopulmonary Exercise testing
- Arterial Blood Gas sampling
- Predictors of high morbidity and mortality
- Initial Testing
- Management: Cranial Irradiation in Small Cell Cancer
- Prophylactic cranial irradiation improves survival
- Auperin (1999) N Engl J Med 341:476-84
- Prevention
- Tobacco Cessation
- Tobacco exposure is the predominant cause of Lung Cancer
- Lung Cancer screening does not change mortality
- Annual Chest CT screening might predispose to cancer
- Screening in U.S. would cost: $12 billion/year
- Routine Lung Cancer screening is not recommended
- Tobacco Cessation
- Prognosis
- Five year survival 14% regardless of screening